Korro Bio submitted an application to Alfred Health Human Ethics Committee in Australia to start a first-in-human Phase 1/2 trial of KRRO-121.
KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide being developed for hyperammonemia in patients with urea cycle disorders.
The study aims to evaluate safety, tolerability, pharmacokinetics, and early activity in healthy volunteers and participants with urea cycle disorders.
KRRO•
